PMID- 36194200
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20221222
IS  - 2410-8650 (Electronic)
IS  - 1607-551X (Linking)
VI  - 38
IP  - 12
DP  - 2022 Dec
TI  - BMI1 induces ubiquitination and protein degradation of Nod-like receptor family 
      CARD domain containing 5 and suppresses human leukocyte antigen class I 
      expression to induce immune escape in non-small cell lung cancer.
PG  - 1190-1202
LID - 10.1002/kjm2.12602 [doi]
AB  - The Nod-like receptor (NLR) family CARD domain containing 5 (NLRC5) has been 
      reported as an activator of human leukocyte antigen (HLA) class I that is 
      responsible for immune activity in cancer treatment. This work focuses on the 
      role of BMI1 proto-oncogene (BMI1) in the NLRC5-HLA class I axis and in immune 
      escape in non-small cell lung cancer (NSCLC). First, immunoblot analysis and/or 
      reverse transcription-quantitative polymerase chain reaction were performed, 
      which identified decreased NLRC5 and HLA class I levels in NSCLC tissues and cell 
      lines. NSCLCs were co-cultured with activated CD8(+) T cells. Overexpression of 
      NLRC5 in NSCLC cells elevated the expression of HLA class I and increased the 
      activity of T cells and IL-2 production, and it reduced the PD-1/PD-L1 levels. 
      The ubiquitination and immunoprecipitation assays confirmed that BMI1 bound to 
      NLRC5 to induce is ubiquitination and protein degradation. Downregulation of BMI1 
      in NSCLC cells elevated NLRC5 and HLA class I levels, and consequently promoted T 
      cell activation and decreased PD-1/PD-L1 levels in the co-culture system. 
      However, overexpression of BMI1 in cells led to inverse trends. In summary, this 
      study demonstrates that BMI1 induces ubiquitination and protein degradation of 
      NLRC5 and suppresses HLA class I expression, which potentially helps immune 
      escape in NSCLC.
CI  - (c) 2022 The Authors. The Kaohsiung Journal of Medical Sciences published by John 
      Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
FAU - Lu, Zhi-Hui
AU  - Lu ZH
AD  - Department of Oncology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Tu, Gan-Jie
AU  - Tu GJ
AD  - Department of Oncology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Fu, Si-Lv
AU  - Fu SL
AD  - Department of Oncology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Shang, Kai
AU  - Shang K
AD  - Department of Oncology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Peng, Su-Juan
AU  - Peng SJ
AD  - Department of Oncology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Chen, Li
AU  - Chen L
AUID- ORCID: 0000-0002-0880-9926
AD  - Department of Oncology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Gu, Xi-Juan
AU  - Gu XJ
AD  - Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20221004
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 0 (B7-H1 Antigen)
RN  - 0 (NLR Proteins)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA Antigens)
RN  - 0 (BMI1 protein, human)
RN  - EC 2.3.2.27 (Polycomb Repressive Complex 1)
RN  - 0 (NLRC5 protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/genetics
MH  - B7-H1 Antigen/metabolism
MH  - CD8-Positive T-Lymphocytes
MH  - Proteolysis
MH  - NLR Proteins/metabolism
MH  - Caspase Activation and Recruitment Domain
MH  - Programmed Cell Death 1 Receptor/metabolism
MH  - Intracellular Signaling Peptides and Proteins/metabolism
MH  - *Lung Neoplasms/genetics
MH  - Histocompatibility Antigens Class I/genetics/metabolism
MH  - Ubiquitination
MH  - HLA Antigens
MH  - Polycomb Repressive Complex 1/genetics/metabolism
OTO - NOTNLM
OT  - BMI1
OT  - HLA class I
OT  - NLRC5
OT  - PD-1/PD-L1
OT  - T cells
EDAT- 2022/10/05 06:00
MHDA- 2022/12/16 06:00
CRDT- 2022/10/04 10:53
PHST- 2022/07/22 00:00 [revised]
PHST- 2022/05/09 00:00 [received]
PHST- 2022/08/29 00:00 [accepted]
PHST- 2022/10/05 06:00 [pubmed]
PHST- 2022/12/16 06:00 [medline]
PHST- 2022/10/04 10:53 [entrez]
AID - 10.1002/kjm2.12602 [doi]
PST - ppublish
SO  - Kaohsiung J Med Sci. 2022 Dec;38(12):1190-1202. doi: 10.1002/kjm2.12602. Epub 
      2022 Oct 4.